Dishman Pharma zooms 20% as merger with arms becomes effective
Tuesday, March 28, 2017, 10:21 AM
Shares of Dishman Pharmaceuticals shot up 20% in Tuesday’s trade after the drugmaker informed exchanges that its amalgamation with Carbogen Amcis (India) (CAIL) and Dishman Care (DCL) has become effective from March 17. But what probably led the stock rally reported that the USFDA approves Tesaro Inc's Ovarian Cancer drug Zejula. Analysts believe Dishman Pharma could be a major beneficiary.